Table 1.
Overview of clinical trials using DNMT inhibitors (monotherapy or combination) in HNSCC.
| Reference/NCT | Status | Phase | DNMT Inhibitor | Chemotherapy/Immunotherapy | Study Duration | Disease Target | Result |
|---|---|---|---|---|---|---|---|
| NCT02178072 | Recruiting | Window study | Azacytidine | 2014-ongoing | HPV-positive HNSCC (resectable disease) | Pending | |
| NCT04252248 | Recruiting | 1b | Decitabine | 2019-ongoing | HPV-positive Anogenital and HNSCC (R/M) |
Pending | |
| NCT03019003 | Recruiting | 1b | Decitabine | Durvalumab | 2017-ongoing | HNSCC (R/M, refractory to immune checkpoint blockade | Pending |
Black, bold font: clinical trial ongoing and results not available yet.